Registry for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to gather information on the effectiveness of treatments for non-small cell lung cancer (NSCLC) over time. It focuses on patients with a specific genetic change called METex14, which influences cancer growth. The study will monitor the efficacy and safety of different treatments for these patients. Individuals with advanced NSCLC who have this genetic change and are receiving systemic therapy (such as chemotherapy) might be suitable candidates for this trial.
As a Phase 3 trial, this study represents the final step before FDA approval, providing access to potentially effective treatments.
Why are researchers excited about this trial?
Researchers are excited about the Met Non Small Cell Cancer Registry because it aims to gather comprehensive data that could lead to more personalized treatments for metastatic non-small cell lung cancer (NSCLC). Unlike current treatments, which often follow a one-size-fits-all approach, this registry seeks to understand the diverse responses patients have to existing therapies. By analyzing genetic and clinical information, the project hopes to uncover new insights and tailor treatments to individual patient profiles, potentially improving outcomes and reducing side effects. This approach represents a shift towards precision medicine, where therapy is customized based on the unique characteristics of each patient’s cancer.
Who Is on the Research Team?
Medical Responsible
Principal Investigator
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Data Collection
Collection of demographic, clinical characteristics, treatment patterns, and outcomes data for NSCLC patients
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
EMD Serono Research & Development Institute, Inc.
Lead Sponsor
Miguel Fernández Alcalde
EMD Serono Research & Development Institute, Inc.
Chief Executive Officer
Bachelor’s Degree in Pharmacy from the University Complutense in Madrid, MBA from the University of Alcalá de Henares, Master’s Degree in Management from IESE Business School
Danny Bar-Zohar
EMD Serono Research & Development Institute, Inc.
Chief Medical Officer since 2022
MD
Merck KGaA, Darmstadt, Germany
Industry Sponsor
Danny Bar-Zohar
Merck KGaA, Darmstadt, Germany
Chief Medical Officer since 2022
MD
Belén Garijo
Merck KGaA, Darmstadt, Germany
Chief Executive Officer since 2021
MD